{"filing":{"accession_number":"0001437749-26-031337","cik":"0001533040","ticker":"PHIO","company_name":"Phio Pharmaceuticals Corp.","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-28","primary_document":"phio20260916_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926031337/phio20260916_8k.htm"},"events":[{"id":35425,"run_id":32627,"accession_number":"0001437749-26-031337","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders voted at the Annual Meeting of Stockholders on three proposals: election of six directors, ratification of Grant Thornton, LLP as independent auditor, and approval of an amendment to the 2020 Long Term Incentive Plan increasing the share reserve by 1,500,000 shares. Detailed voting results for each proposal and director nominee were disclosed.","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39463,"accession_number":"0001437749-26-031337","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2020 Long Term Incentive Plan that increased the share reserve by 1,500,000 shares. This is a compensatory arrangement amendment affecting the pool of equity available for director and officer grants, which falls squarely within exec_compensation. The material increase in authorized shares for equity compensation is a significant governance and capital allocation decision affecting existing and future executive incentives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:09:52.599793+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39464,"accession_number":"0001437749-26-031337","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of an Annual Meeting of Stockholders where shareholders voted on three proposals: (1) election of six directors, (2) ratification of Grant Thornton, LLP as independent auditor, and (3) approval of a Plan Amendment to increase shares available under the 2020 Plan by 1,500,000. The detailed voting tallies for each proposal and nominee are provided, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:09:52.599793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39463,"accession_number":"0001437749-26-031337","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2020 Long Term Incentive Plan that increased the share reserve by 1,500,000 shares. This is a compensatory arrangement amendment affecting the pool of equity available for director and officer grants, which falls squarely within exec_compensation. The material increase in authorized shares for equity compensation is a significant governance and capital allocation decision affecting existing and future executive incentives.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:09:52.599793+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-09-28"},{"id":39464,"accession_number":"0001437749-26-031337","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of an Annual Meeting of Stockholders where shareholders voted on three proposals: (1) election of six directors, (2) ratification of Grant Thornton, LLP as independent auditor, and (3) approval of a Plan Amendment to increase shares available under the 2020 Plan by 1,500,000. The detailed voting tallies for each proposal and nominee are provided, which is the core disclosure required under Item 5.07 for shareholder vote results.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T20:09:52.599793+00:00","company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","filing_date":"2026-09-28"}]}